跳至主要内容
临床试验/KCT0007617
KCT0007617尚未招募未知

Observational study of COVID-19 prophylactic antibody (Tixagevimab-Cilgavimab) administration in immunosuppressed patients

lsan Univeristy Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
18(Year) 至 o Limit(—)
性别
All

入选标准

  • 1) 19 years of age or older
  • 2) Weight 40kg or more
  • 3) If there is no confirmed history of COVID-19 within the last 7 days as of the scheduled administration date of Evusheld
  • 4) Lymphoma (morbidity code: C81, C82, C83, C84, C85, C86), multiple myeloma (C90), acute leukemia (C92, C95) patients who have treated with immunosuppressive agents or chemotherapy within 2 months
  • 5) Patients who have received an allogeneic hematopoietic stem cell transplant within 4 months
  • 6) Patients who have received autologous hematopoietic stem cell transplantation within 2 months
  • 7) Those who voluntarily decided to participate in this study and gave their written consent

排除标准

  • 1) Contraindications to Evusheld administration
  • 2) denial of consent

研究者

发起方
lsan Univeristy Hospital

相似试验